HEPATIC IMPAIRMENT

This study is testing how liver problems affect how the body processes a single dose of the cancer drug inavolisib. Researchers will compare people with moderate or severe liver impairment to healthy people with normal liver function. The goal is to understand if liver problems c…

This early study aims to understand how liver problems affect the way the body processes a cancer drug called tazemetostat. It will compare blood levels of the drug in people with advanced cancer who have normal liver function to those with moderate or severe liver impairment. Th…

This study aims to understand how mild to moderate liver problems affect how the body processes an experimental drug called tasurgratinib. Researchers will compare drug levels in 18 participants—some with liver impairment and some healthy—after a single dose. The goal is to gathe…

This early-stage study aims to understand how a single dose of a new antiviral drug combination is processed by the body in people with severe liver or kidney impairment. It will compare the drug's levels and safety in these participants to a matched group of healthy volunteers. …

This early-stage study aims to understand how a new medicine, PF-07328948, is processed in the bodies of people with different levels of liver impairment compared to healthy people. It will enroll 26 adults, some with stable liver disease and some without, who will take a single …

This early-stage study aims to understand how a potential new drug called radiprodil is processed by the body in people with different levels of liver impairment. The drug is being developed for certain genetic brain disorders. About 40 adults, some with liver problems and some h…

This early-stage study aims to understand how liver impairment affects how the body processes an experimental drug called MK-1084 (calderasib). Researchers will compare drug levels and safety in 58 participants, some with stable liver disease and some who are healthy. The goal is…

This study aims to understand how a drug called Saroglitazar is processed by the body in people with liver damage caused by a specific type of liver disease. It will compare 30 participants with mild, moderate, or severe liver damage to people with normal liver function. The main…

This early-stage study aims to understand how a single dose of the drug quizartinib is processed by the body in people with severe liver impairment. It will compare 12 participants with poor liver function to healthy volunteers, measuring drug levels in the blood and checking for…

This early-stage study aims to understand how liver problems affect how much of a new drug, BI 1291583, gets into a person's bloodstream. The drug is being developed to treat bronchiectasis, a chronic lung disease. Researchers will compare blood levels in 32 adults with varying d…